Either knockdown of Src by shRNA (A) or inhibition of Src phosphorylation by saracatinib or dasatinib (B) promotes reversible EMT in mesenchymal-like HNSCC cells. The gene discussed is SRC; the disease is head and neck squamous cell carcinoma.